ENSYSCE BIOSCIENCES INC (ENSC) Stock Fundamental Analysis
USA - NASDAQ:ENSC - US2936025046 - Common Stock
2.03 USD
-0.03 (-1.46%)
ENSC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. The financial health of ENSC is average, but there are quite some concerns on its profitability. ENSC is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year ENSC has reported negative net income.
In the past year ENSC has reported a negative cash flow from operations.
In the past 5 years ENSC reported 4 times negative net income.
In the past 5 years ENSC always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of ENSC (-118.07%) is worse than 79.10% of its industry peers.
The Return On Equity of ENSC (-194.20%) is worse than 67.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -118.07% | ||
| ROE | -194.2% | ||
| ROIC | N/A |
ROA(3y)-319.99%
ROA(5y)-221.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ENSC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ENSC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ENSC has been reduced compared to 5 years ago.
ENSC has a better debt/assets ratio than last year.
2.2 Solvency
ENSC has an Altman-Z score of -33.79. This is a bad value and indicates that ENSC is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -33.79, ENSC is not doing good in the industry: 90.40% of the companies in the same industry are doing better.
ENSC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -33.79 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 2.10 indicates that ENSC has no problem at all paying its short term obligations.
ENSC has a worse Current ratio (2.10) than 73.45% of its industry peers.
ENSC has a Quick Ratio of 2.10. This indicates that ENSC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.10, ENSC is doing worse than 71.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.1 | ||
| Quick Ratio | 2.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 91.07% over the past year.
Looking at the last year, ENSC shows a very strong growth in Revenue. The Revenue has grown by 413.95%.
Measured over the past years, ENSC shows a quite strong growth in Revenue. The Revenue has been growing by 13.86% on average per year.
EPS 1Y (TTM)91.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.06%
Revenue 1Y (TTM)413.95%
Revenue growth 3Y13.86%
Revenue growth 5YN/A
Sales Q2Q%654.13%
3.2 Future
Based on estimates for the next years, ENSC will show a very strong growth in Earnings Per Share. The EPS will grow by 41.95% on average per year.
ENSC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 176.07% yearly.
EPS Next Y68.03%
EPS Next 2Y41.95%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-33.73%
Revenue Next 2Y-41.42%
Revenue Next 3Y176.07%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ENSC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
ENSC is valuated reasonably with a Price/Forward Earnings ratio of 10.21.
Based on the Price/Forward Earnings ratio, ENSC is valued cheaply inside the industry as 97.36% of the companies are valued more expensively.
ENSC is valuated cheaply when we compare the Price/Forward Earnings ratio to 33.61, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.21 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ENSC's earnings are expected to grow with 41.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.95%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ENSC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ENSC (11/10/2025, 8:00:02 PM)
2.03
-0.03 (-1.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners3.2%
Inst Owner Change25.29%
Ins Owners0.35%
Ins Owner Change0%
Market Cap6.03M
Revenue(TTM)7.41M
Net Income(TTM)-6.58M
Analysts82.86
Price Target26.75 (1217.73%)
Short Float %5.69%
Short Ratio1.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.58%
Min EPS beat(2)34.36%
Max EPS beat(2)54.8%
EPS beat(4)3
Avg EPS beat(4)52.12%
Min EPS beat(4)-3.95%
Max EPS beat(4)123.26%
EPS beat(8)6
Avg EPS beat(8)32.27%
EPS beat(12)10
Avg EPS beat(12)41.51%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.37%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.21 | ||
| P/S | 0.81 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.78 | ||
| P/tB | 1.78 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.03
EYN/A
EPS(NY)0.2
Fwd EY9.8%
FCF(TTM)-2.09
FCFYN/A
OCF(TTM)-2.09
OCFYN/A
SpS2.5
BVpS1.14
TBVpS1.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -118.07% | ||
| ROE | -194.2% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-319.99%
ROA(5y)-221.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover1.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.1 | ||
| Quick Ratio | 2.1 | ||
| Altman-Z | -33.79 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.06%
EPS Next Y68.03%
EPS Next 2Y41.95%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)413.95%
Revenue growth 3Y13.86%
Revenue growth 5YN/A
Sales Q2Q%654.13%
Revenue Next Year-33.73%
Revenue Next 2Y-41.42%
Revenue Next 3Y176.07%
Revenue Next 5YN/A
EBIT growth 1Y31.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-209.36%
EBIT Next 3Y51.15%
EBIT Next 5YN/A
FCF growth 1Y62.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.95%
OCF growth 3YN/A
OCF growth 5YN/A
ENSYSCE BIOSCIENCES INC / ENSC FAQ
Can you provide the ChartMill fundamental rating for ENSYSCE BIOSCIENCES INC?
ChartMill assigns a fundamental rating of 4 / 10 to ENSC.
Can you provide the valuation status for ENSYSCE BIOSCIENCES INC?
ChartMill assigns a valuation rating of 4 / 10 to ENSYSCE BIOSCIENCES INC (ENSC). This can be considered as Fairly Valued.
Can you provide the profitability details for ENSYSCE BIOSCIENCES INC?
ENSYSCE BIOSCIENCES INC (ENSC) has a profitability rating of 0 / 10.
Can you provide the financial health for ENSC stock?
The financial health rating of ENSYSCE BIOSCIENCES INC (ENSC) is 6 / 10.